Evidence map›Paper›PMID 33880669›Full record

ArticleMedical oncology (Northwood, London, England)2021

H

Jianqiang Chen, Xiangxiang Jin, Zhe Shen, Yanan Mei, Jufan Zhu, Xiaodan Zhang, Guang Liang, Xiaohui Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Systemic Effects of Photoactivated 5,10,15,20-tetrakis(Biotech (Basel (Switzerland)) · 2024
    Article
  4. Crosstalk between G-quadruplex and ROS.Cell death & disease · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jianqiang ChenChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, People's Republic of China.
Xiangxiang JinChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, People's Republic of China.
Zhe ShenChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, People's Republic of China.
Yanan MeiChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, People's Republic of China.
Jufan ZhuChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, People's Republic of China.
Xiaodan ZhangDepartment of Pharmacy, The Seventh People's Hospital of Wenzhou, Wenzhou, 325006, Zhejiang, People's Republic of China. ha.daybreak@163.com.
Guang LiangChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, People's Republic of China. wzmcliangguang@163.com.
Xiaohui ZhengChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, People's Republic of China. zhengxh@wmu.edu.cn.ORCID http://orcid.org/0000-0002-1307-1209
Wenzhou Medical University · CNWenzhou City People's Hospital · CN

Funding

National Natural Science Foundation of China 21701194Wenzhou Basic Medical and Health Technology Project Y20180177Wenzhou Medical University Talent Start-up Fund QTJ17022
6 · The paper itself

Abstract

Cancer is one of the diseases that threatens human health and is a leading cause of mortality worldwide. High levels of reactive oxygen species (ROS) have been observed in cancer tissues compared with normal tissues in vivo, and it is not yet known how this influences chemotherapeutic drug action. Cationic porphyrin 5,10,15,20-tetra-(N-methyl-4-pyridyl) porphyrin (TMPyP4) is a photosensitizer used in photodynamic therapy (PDT) and a telomerase inhibitor used in the treatment of telomerase-positive cancer. Here, we investigated the anticancer activity of TMPyP4 in A549 and PANC cells cultured in H

Indexed as

A549 CellsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorComet AssayDNA DamageHepatocytesHumansHydrogen PeroxideMembrane Potential, MitochondrialMitochondriaPancreatic NeoplasmsPorphyrinsReactive Oxygen SpeciesTumor MicroenvironmentHydrogen PeroxidePorphyrinsReactive Oxygen Speciestetra(4-N-methylpyridyl)porphineApoptosisDNA damageROSTMPyP4Tumor microenvironment

Identifiers

PMID33880669
OpenAlexW3132096010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.